Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Revolutionary Platform to Decipher Immunogenicity of Tumour Neoantigens- the Ultimate Targets for Future Immunotherapies to Eradicate Cancer

Project description

The next chapter in anticancer therapies

A new path towards developing novel and effective anticancer therapies is on the horizon. While immunotherapy is already being used to help patients with hard-to-treat tumours, the benefits are unevenly distributed. Clinical efficacy varies greatly and side effects persist. In this context, the EU-funded DECOD-Ag project will work towards an unbiased high-throughput transformative immunogenicity profiling platform. This will identify immunogenic tumour neoantigens with enabling technologies. Based on random mutagenesis and artificial antigen-presenting cells, this high-throughput screen technology will be developed by world-leading, interdisciplinary scientists with expertise in cancer immunotherapy, bioinformatics, peptidomics, mass spectrometry, immune monitoring, and clinical and translational medicine.

Objective

Immunotherapy has revolutionised cancer treatment, providing survival benefits in patients with hard-to-treat tumours. Tragically, these benefits are unevenly distributed. Clinical efficacy varies dramatically between (and within) cancer types, and severe side-effects persist. To address this, new treatment strategies seek the rational design of personalised therapies to achieve full eradication of most cancers. Such a vision can be achieved by inducing immune responses against the ultimate tumour-specific targets: immunogenic tumour neoantigens (iNeoAg). However, a major limitation is the lack of technologies to identify iNeoAg from the thousands of background mutations in tumours. The DECOD-Ag consortium envisions a revolutionary technology realising an unbiased high-throughput transformative immunogenicity profiling platform that, for the first time, uniquely identifies iNeoAgs with the following enabling technologies: i) high throughput screening technology based on random mutagenesis and artificial antigen-presenting cells, to categorise immune recognition triplets (MHC-neoantigen-TCR), define the rules of neoantigen-T cell engagement and the immunogenicity of the neoantigen; ii) robust in silico prediction algorithms to predict neoantigen immunogenicity and neoantigen-T cell pairing; and iii) clinical validation workflow combining multiple advanced immune monitoring technologies. The DECOD-Ag project will be conducted by world-leading, interdisciplinary scientists, with expertise in cancer immunotherapy, bioinformatics, peptidomics, mass spectrometry, immune monitoring, clinical and translational medicine. The DECOD-Ag platform and GENESIS predictor will lead to a new frontier towards developing novel and effective anticancer therapies, with the radical potential to fully eradicate any tumour in any patient.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

RIA - Research and Innovation action

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) H2020-FETOPEN-2018-2020

See all projects funded under this call

Coordinator

UNIVERSITY COLLEGE LONDON
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 1 005 647,50
Address
GOWER STREET
WC1E 6BT London
United Kingdom

See on map

Region
London Inner London — West Camden and City of London
Activity type
Higher or Secondary Education Establishments
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 1 005 647,50

Participants (4)

My booklet 0 0